APA

Mross K., Scheulen M. E., Licht T., Unger C., Richly H., Stern A. C., Kutz K., Camboni M. G., Barbieri P., Verdi E., Vincenzi B. & Bernareggi A. (20041025). Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR). : Anti-cancer drugs.

Chicago

Mross Klaus, Scheulen Max E, Licht Thomas, Unger Clemens, Richly Heike, Stern Angelika C, Kutz Klaus, Camboni Maria G, Barbieri Paola, Verdi Elena, Vincenzi Beatrice and Bernareggi Alberto. 20041025. Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR). : Anti-cancer drugs.

Harvard

Mross K., Scheulen M. E., Licht T., Unger C., Richly H., Stern A. C., Kutz K., Camboni M. G., Barbieri P., Verdi E., Vincenzi B. and Bernareggi A. (20041025). Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR). : Anti-cancer drugs.

MLA

Mross Klaus, Scheulen Max E, Licht Thomas, Unger Clemens, Richly Heike, Stern Angelika C, Kutz Klaus, Camboni Maria G, Barbieri Paola, Verdi Elena, Vincenzi Beatrice and Bernareggi Alberto. Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR). : Anti-cancer drugs. 20041025.